What Does the DEA Telemedicine Rule Mean for Telehealth Ads in 2026?

What this means for you

• Until December 31, 2026, DEA-registered practitioners can prescribe Schedule II to V controlled medications by telemedicine without a prior in-person evaluation, as they have since March 2020.
• A permanent rule is close but not public. OMB's Office of Information and Regulatory Affairs received DEA's final special registration rule on August 25, 2026, and the 2026 regulatory agenda lists final action for November 2026.
• The January 2025 proposal would have created special registrations with heavier prescribing, recordkeeping and reporting duties, and required certain direct-to-consumer telemedicine platforms to register with DEA. The final text may differ.
• Ads should sell the clinical program, not a remote prescription. Write copy and pages that stay true if some patients need an in-person visit in 2027.
• Plan first-quarter 2027 budgets as scenarios, and have healthcare counsel review the visit model before year end.

MedScale Health, a paid acquisition agency for telehealth brands and clinics, runs paid acquisition for telehealth brands in categories that involve controlled substances, including testosterone, ADHD medication and ketamine. This page explains where the federal rules stand and what that means for ads, pages and budgets. It is marketing guidance, not legal advice: have healthcare counsel confirm how any DEA rule applies to your prescribing model.

What the fourth extension does

Federal Register document 2025-24123, published December 31, 2025 by DEA jointly with HHS, is effective from January 1, 2026 through December 31, 2026. It extends the telemedicine flexibilities for prescribing controlled substances that have been in place since March 2020. Like the three extensions before it, it lets DEA-registered practitioners prescribe Schedule II to V controlled substances remotely without an in-person medical evaluation. DEA says the purpose is to avoid a sudden end to that access, which stakeholders call the telemedicine cliff, while it finishes permanent rules.

Two narrower rules sit beside it. Final rules on buprenorphine treatment for opioid use disorder by telemedicine, and on continuity of care for Veterans Affairs patients, took effect on December 31, 2025, according to the same document. Practitioners may still use the temporary flexibilities, which impose fewer requirements, while they last.

Which telehealth categories this covers

• ADHD: amphetamine, methylphenidate and lisdexamfetamine are Schedule II controlled substances (21 CFR 1308.12).
• Ketamine: Schedule III (21 CFR 1308.13).
• TRT: testosterone falls under anabolic steroids, which are listed in Schedule III (21 CFR 1308.13).

The ad platform rules do not change on December 31. Meta's Drugs and Pharmaceuticals policy still requires LegitScript certification and Meta's authorization before a telehealth provider promotes a prescription drug, and Google still requires certification for telemedicine providers. LegitScript's application asks for DEA certificate information where controlled substances are involved, and its FAQ warns that ketamine-related services may face extra advertising restrictions that LegitScript cannot predict.

What is known about the permanent rule

Reginfo.gov, the government's regulatory tracking site, shows that OMB's Office of Information and Regulatory Affairs received DEA's final rule on Special Registrations for Telemedicine and Limited State Telemedicine Registrations on August 25, 2026, marked economically significant. The 2026 Unified Agenda lists final action for November 2026 and says DEA has been reviewing more than 6,400 public comments on the proposal. As of October 5, 2026, no final rule and no further extension had been published in the Federal Register. An agenda date is a plan, not a promise.

The proposal it builds on, Federal Register document 2025-01099 from January 17, 2025, would have set up a special registration framework with three types of registration and heavier prescription, recordkeeping and reporting requirements. DEA's agenda entry adds that the proposal would have let registered practitioners prescribe by audio-video telemedicine, and in limited cases audio-only, without ever seeing the patient in person, and would have required certain direct-to-consumer telemedicine platforms to register with DEA. None of that is final until DEA publishes it.

Three scenarios to plan for

• A final rule is published with a start date. Read the effective date and any transition period, check which prescribers and which platform roles need a registration, then update intake, landing pages and ads to match.
• Another extension is published. The current model continues for the new term. Keep the scenario plan on file, because the question returns at the next deadline.
• The flexibilities end with nothing in their place. The Ryan Haight Act's general requirement of an in-person medical evaluation before prescribing a controlled substance applies unless an exception fits. Counsel decides what that means for new and existing patients.

What to change in the ads now

• Sell the program: the clinician, the assessment, labs where relevant, and follow-up care. Avoid copy that sells a prescription, such as "get ADHD meds online", and avoid promising that no visit will ever be needed.
• Prepare a landing page and intake variant for an in-person or hybrid first visit, so the switch takes days, not weeks.
• Keep state routing and visit type in the intake, so ads can keep running in states where the model still works.
• If the model changes, tell LegitScript. Its terms require notice within 30 days of changes to licensure, regulatory status or DEA registration.

Tracking does not change with the rule. Event names and page addresses should never carry a drug or a condition. MedScale tracks server-side under a BAA with neutral event names, and no names, emails, phone numbers, IP addresses or browser IDs go to any ad platform.

Budget timing

Treat December as a planning month. Avoid committing January spend or creative that depends on a remote-only first visit until the Federal Register shows which scenario applies. Keep the always-on program campaigns running, because they don't depend on how the first visit happens.

What MedScale does

MedScale Health builds controlled-substance telehealth campaigns around the clinical program, with LegitScript certification help, Meta authorization and Google certification where the brand needs them, pre-checked creative, and landing page variants ready for each DEA scenario. MedScale watches the Federal Register and reginfo.gov for the final rule and updates client plans when it lands. No outcome is guaranteed. The free growth audit at medscale.health/audit reviews your ads, pages and tracking against these rules.